- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Prostate cancer
- Meeting Date: July 2020
- Public Summary Document (PSD) July 2020 PBAC Meeting - (PDF 1480KB)
- Public Summary Document (PSD) July 2020 PBAC Meeting - (Word 304KB)
Darolutamide – July 2020
Darolutamide: Tablet 300 mg; Nubeqa®
Last updated
13 November 2020